UTRN and Duchenne muscular dystrophy: Here, we report two new cell cultured models that can be successfully used for preclinical assessment of new DMD therapies: a culture that replicates a patient’s deletion (DMDΔ52-Model) and another that overexpresses utrophin (DMD-UTRN-Model).